What controversy? Eli Lilly plots Alzheimer's BLA filing later this year as FDA taps more anti-amyloid drugs as breakthroughs
The FDA is keeping the good news coming for Alzheimer’s drug developers. And Eli Lilly is taking them up on it.
Amid continued controversy around whether Biogen’s new flagship drug, Aduhelm, should have been approved at all — and swelling, heated debates surrounding its $56,000 price tag — the agency had no issue handing them and their Japanese partner Eisai a breakthrough therapy designation for a second anti-amyloid beta antibody, lecanemab, late Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.